RARA (retinoic acid receptor alpha) is a ligand-activated nuclear receptor that functions as a master regulator of gene expression in response to retinoic acid signaling 1. RARA forms heterodimers with RXR that bind to retinoic acid response elements (RARE) in target gene promoters 2. In the absence of ligand, RXR-RAR heterodimers recruit corepressor complexes containing histone deacetylases that suppress transcription through chr17 condensation 1. Upon ligand binding, corepressors dissociate and coactivators are recruited, leading to histone acetylation and transcriptional activation 3. RARA regulates essential developmental processes including spermatogenesis, skeletal growth, and vascular endothelial function through microRNA-dependent mechanisms 4. Clinically, RARA is the central target in acute promyelocytic leukemia (APL), which arises from chr17 translocations generating PML-RARA fusion proteins 5. PML-RARA aberrantly blocks myeloid differentiation by deregulating RARA target gene expression and disrupting normal transcriptional control 6. Notably, PML-RARA-driven transformation is reversible: combination therapy with retinoic acid and arsenic trioxide directly targets PML-RARA, restoring differentiation and achieving >90% long-term survival rates, establishing APL as a paradigm for oncoprotein-targeted cure 5. ATRA responsiveness depends on intact ligand-binding domain function; truncations in the ligand-binding domain result in ATRA resistance in atypical APL variants 7.